343 related articles for article (PubMed ID: 38347643)
1. Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A; Perol M; Banna GL; Parikh K; Addeo A
Biomark Res; 2024 Feb; 12(1):24. PubMed ID: 38347643
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
König D; Savic Prince S; Rothschild SI
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671873
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Chevallier M; Borgeaud M; Addeo A; Friedlaender A
World J Clin Oncol; 2021 Apr; 12(4):217-237. PubMed ID: 33959476
[TBL] [Abstract][Full Text] [Related]
4. An odd dancing couple. Non-small cell lung carcinoma with coexisting EGFR mutation and NTRK-1 translocation: A case report.
Robledano R; Lozano MD
Diagn Cytopathol; 2024 Apr; ():. PubMed ID: 38634549
[TBL] [Abstract][Full Text] [Related]
5. Beyond
Gkolfinopoulos S; Mountzios G
Ann Transl Med; 2018 Apr; 6(8):142. PubMed ID: 29862231
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers.
Somme LB; Chouaid C; Moinard-Butot F; Barbe-Richaud JB; Greillier L; Schott R
BioDrugs; 2024 May; ():. PubMed ID: 38767823
[TBL] [Abstract][Full Text] [Related]
7. Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.
Chalela R; Curull V; Enríquez C; Pijuan L; Bellosillo B; Gea J
J Thorac Dis; 2017 Jul; 9(7):2142-2158. PubMed ID: 28840016
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation.
Chung C; Umoru G
J Oncol Pharm Pract; 2024 Apr; ():10781552241242684. PubMed ID: 38576390
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer.
Lengel HB; Connolly JG; Jones GD; Caso R; Zhou J; Sanchez-Vega F; Mastrogiacomo B; Isbell JM; Li BT; Liu Y; Rekhtman N; Jones DR
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359558
[TBL] [Abstract][Full Text] [Related]
10. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
Stein MK; Oluoha O; Patel K; VanderWalde A
J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34198738
[TBL] [Abstract][Full Text] [Related]
11. The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast.
Hirsch FR; Kim C
Oncol Ther; 2024 Mar; ():. PubMed ID: 38536631
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer in never smokers-the East Asian experience.
Zhou F; Zhou C
Transl Lung Cancer Res; 2018 Aug; 7(4):450-463. PubMed ID: 30225210
[TBL] [Abstract][Full Text] [Related]
13. Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine.
Mie T; Sasaki T; Okamoto T; Furukawa T; Takeda T; Kasuga A; Ozaka M; Sasahira N
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473240
[TBL] [Abstract][Full Text] [Related]
14. Targeted Lung Cancer Treatments and Eye Metastasis.
Zarogoulidis P; Baka S; Labaki S; Lazaridis G; Trakada G
Med Hypothesis Discov Innov Ophthalmol; 2017; 6(1):10-13. PubMed ID: 28428969
[TBL] [Abstract][Full Text] [Related]
15. Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists.
Bui KT; Cooper WA; Kao S; Boyer M
J Clin Med; 2018 Jul; 7(8):. PubMed ID: 30065223
[TBL] [Abstract][Full Text] [Related]
16. Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.
Daoud A; Chu QS
Front Oncol; 2017; 7():222. PubMed ID: 29034207
[TBL] [Abstract][Full Text] [Related]
17. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
Garinet S; Laurent-Puig P; Blons H; Oudart JB
J Clin Med; 2018 Jun; 7(6):. PubMed ID: 29890761
[TBL] [Abstract][Full Text] [Related]
18. Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.
Pecci F; Nakazawa S; Ricciuti B; Harada G; Lee JK; Alessi JV; Barrichello A; Vaz VR; Lamberti G; Di Federico A; Gandhi MM; Gazgalis D; Feng WW; Jiang J; Baldacci S; Locquet MA; Gottlieb FH; Chen MF; Lee E; Haradon D; Smokovich A; Voligny E; Nguyen T; Goel VK; Zimmerman Z; Atwal S; Wang X; Bahcall M; Heist RS; Iqbal S; Gandhi N; Elliott A; Vanderwalde AM; Ma PC; Halmos B; Liu SV; Che J; Schrock AB; Drilon A; Janne PA; Awad MM
Cancer Discov; 2024 Apr; ():. PubMed ID: 38564707
[TBL] [Abstract][Full Text] [Related]
19. Genomic medicine advances for brain tumors.
Koizumi S; Oishi T; Iwaizumi M; Kurozumi K
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38727852
[TBL] [Abstract][Full Text] [Related]
20. Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses.
Nikanjam M; Wells K; Kato S; Adashek JJ; Block S; Kurzrock R
Med; 2024 May; ():. PubMed ID: 38749442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
